High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms

被引:20
|
作者
Chan, David L. [1 ,2 ,3 ,4 ]
Bernard, Elizabeth J. [1 ]
Schembri, Geoffrey [1 ]
Roach, Paul J. [1 ]
Johnson, Meaghan [1 ]
Pavlakis, Nick [2 ,3 ]
Clarke, Stephen [2 ,3 ]
Bailey, Dale L. [1 ,4 ]
机构
[1] Royal North Shore Hosp, Dept Nucl Med, St Leonards, NSW, Australia
[2] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW, Australia
[3] Univ Sydney, Kolling Inst, Bill Walsh Translat Canc Res Lab, Sydney, NSW, Australia
[4] Sydney Vital Translat Canc Res Ctr, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Neuroendocrine neoplasm; Prognosis; Positron emission tomography; F-18-FDG PET/CT; CANCER; PARAMETERS; INDEX;
D O I
10.1159/000504673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction:18-Fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) avidity in neuroendocrine neoplasms (NENs) has been associated with higher-grade disease. F-18-FDG avidity and high SUVmax have been demonstrated to predict poor outcome. Quantitative metrics of F-18-FDG PET, specifically metabolic tumour volume (MTV) and total lesion glycolysis (TLG), have been shown to be prognostic factors in other malignancies, but these have not been investigated to date in NENs.Methods:Patients with NEN undergoing F-18-FDG at Royal North Shore Hospital from 2012 to 2018 were included. Images were analysed with automated segmentation (SUV cut-off of 4) followed by contour verification by a nuclear medicine physician and manual segmentation where required. Variables collected included patient age, histological grade, MTV, TLG, and SUVmax/SUVmean. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). Univariate (UV) and multivariate (MV) analyses were performed for OS and PFS for MTV and TLG separately. For UV analysis, the median MTV and TLG were used to dichotomise the cohort. MTV/TLG for NENs of different histological grade were compared using ANOVA.Results:One hundred and ninety patients were included (median age 63.5, 49% female). Primary site: 42% small bowel, 32% pancreas, 15% other gastrointestinal, 6% lung, 6% other. Grade for gastroenteropancreatic NENs and bronchial NEN: G1/typical carcinoid 37%, G2/atypical carcinoid 40%, G3/large-cell/small-cell neuroendocrine carcinoma 16%, unknown 8%. Median MTV was 4.83 mL (range 0-3,161 mL) and median TLG was 29.22. Patients with high MTV had worse median OS compared to those with low MTV (29.7 months vs. not reached, HR 4.1, 95% CI 2.25-7.49,p< 0.00001). Considered as a continuous variable, MTV predicted for poorer OS on UV (p< 0.00001) and MV (p= 0.003) analyses. Whilst histological grade was significant on both UV and MV, SUVmax was significant on UV (p< 0.00001) but not MV (p= 0.76). Tumours of higher grade had higher MTV (mean MTV - G1: 39.6 mL, G2: 107 mL, G3: 337 mL;p= 0.0001 by ANOVA).Conclusions:Quantitative analysis of F-18-FDG PET in NEN is feasible. High MTV/TLG are predictors of poor prognosis in NEN. Further analyses are underway to investigate a larger cohort of NEN patients.
引用
收藏
页码:950 / 958
页数:9
相关论文
共 50 条
  • [1] Metabolic tumour volume (MTV) on 18-fluorodeoxyglucose positron emission tomography (FDGPET) as a prognostic marker of survival in patients with metastatic neuroendocrine neoplasms (mNENs) receiving 177Lutetium-DOTA-octreotate (Lutate)
    De Silva, Madhawa
    Chan, David
    Bernard, Elizabeth
    Connor, Alice
    Mascall, Sophie
    Bailey, Dale
    Roach, Paul
    Pavlakis, Nick
    Schembri, Geoffrey
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 118 - 118
  • [2] Positron emission tomography with 18-fluorodeoxyglucose and sarcoma
    Carmoi, Thierry
    Bonardel, Gerald
    Gontier, Eric
    Algayres, Jean-Pierre
    PRESSE MEDICALE, 2010, 39 (12): : 1346 - 1347
  • [3] 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors
    Binderup, Tina
    Knigge, Ulrich
    Loft, Annika
    Federspiel, Birgitte
    Kjaer, Andreas
    CLINICAL CANCER RESEARCH, 2010, 16 (03) : 978 - 985
  • [4] 18-Fluorodeoxyglucose positron emission tomography and pancreatic cancer
    Pedrazzoli, S
    Pasquali, C
    Sperti, C
    Chierichetti, F
    DIGESTIVE SURGERY, 2005, 22 (06) : 467 - 468
  • [5] 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma
    Sperti, C
    Pasquali, C
    Chierichetti, F
    Ferronato, A
    Decet, G
    Pedrazzoli, S
    JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (08) : 953 - 959
  • [6] 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma
    Cosimo Sperti
    Claudio Pasquali
    Franca Chierichetti
    Andrea Ferronato
    Giandomenico Decet
    Sergio Pedrazzoli
    Journal of Gastrointestinal Surgery, 2003, 7 : 953 - 960
  • [7] 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma
    Kyohei Ariake
    Fuyuhiko Motoi
    Hideo Shimomura
    Masamichi Mizuma
    Shimpei Maeda
    Chiaki Terao
    Yasuko Tatewaki
    Hideo Ohtsuka
    Koji Fukase
    Kunihiro Masuda
    Hiroki Hayashi
    Tatsuyuki Takadate
    Takeshi Naitoh
    Yasuyuki Taki
    Michiaki Unno
    Journal of Gastrointestinal Surgery, 2018, 22 : 279 - 287
  • [8] 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma
    Ariake, Kyohei
    Motoi, Fuyuhiko
    Shimomura, Hideo
    Mizuma, Masamichi
    Maeda, Shimpei
    Terao, Chiaki
    Tatewaki, Yasuko
    Ohtsuka, Hideo
    Fukase, Koji
    Masuda, Kunihiro
    Hayashi, Hiroki
    Takadate, Tatsuyuki
    Naitoh, Takeshi
    Taki, Yasuyuki
    Unno, Michiaki
    JOURNAL OF GASTROINTESTINAL SURGERY, 2018, 22 (02) : 279 - 287
  • [9] Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms
    Sperti, Cosimo
    Pasquali, Claudio
    Fiore, Vittorio
    Bissoli, Sergio
    Chierichetti, Franca
    Liessi, Guido
    Pedrazzoli, Sergio
    AMERICAN JOURNAL OF SURGERY, 2006, 191 (06): : 743 - 748
  • [10] An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging
    Paquet, P
    Henry, F
    Belhocine, T
    Hustinx, R
    Najjar, F
    Piérard-Franchimont, C
    Piérard, GE
    Rigo, P
    DERMATOLOGY, 2000, 200 (02) : 167 - 169